Bayer’s New CFO Steps Into the Crosshairs of a $33 Billion Debt and a Supreme Court Pivot

Bayer battles 100,000+ Roundup lawsuits as Supreme Court hears key case; pharma sales surge 68% but debt hits €33B, with new CFO appointed.

The Leverkusen-based conglomerate is navigating one of the most intricate periods in its modern history, where a promising pharmaceutical pipeline is locked in a tug-of-war with a legal quagmire that threatens to drain billions from its balance sheet. On Monday, the US Supreme Court heard oral arguments in the case of Durnell v. Monsanto, a pivotal moment that could determine the fate of more than 100,000 outstanding Roundup lawsuits. Observers described the justices as deeply divided, with a ruling expected by the end of the court’s term in June. The stakes are colossal: Bayer has set aside roughly €11.8 billion in provisions for these legal battles, but a negative verdict could force the company to dig far deeper.

Against this backdrop, the supervisory board has appointed Judith Hartmann as the new chief financial officer, effective at the end of May 2026. She will succeed Wolfgang Nickl at a time when the company’s finances are under severe strain. Bayer expects to spend approximately €5 billion this year alone on legal settlements, primarily tied to US glyphosate cases. Meanwhile, the group’s net financial debt is projected to climb to as much as €33 billion, while free cash flow remains deeply negative for the current year.

The market has responded with caution. The stock slipped 9% over the past week, closing at €36.45, though it still holds a solid gain on a year-to-date basis. On Thursday, the shares recovered slightly to €37.09, helped by a post-dividend bounce, but remain down roughly 7% on the week. The ex-dividend adjustment, which saw a statutory minimum payout of €0.11 per share, added to the pressure.

Pharma’s Bright Spot: Nubeqa and Kerendia Surge 68%

Amid the legal turmoil, Bayer’s pharmaceuticals division is delivering a much-needed boost. The company’s strategy of offsetting expiring patents on older drugs with new blockbusters is gaining traction. Last year, the cancer drug Nubeqa and the kidney treatment Kerendia posted a combined revenue jump of 68%, comfortably exceeding management’s initial expectations. The heart medication Beyonttra has also outperformed internal forecasts since its launch, while the hormone-free menopause treatment Lynkuet is now poised for a European rollout following its US debut.

However, the US market presents fresh headwinds. Potential tariffs on patented medicines are forcing Bayer to explore expanding local production, and growing political pressure on drug pricing is adding to the complexity. The company is also pushing ahead in its agricultural division, Crop Science, where it plans to launch ten new blockbuster products over the next decade. The insecticide Plenexos is slated for a Brazilian launch later this year.

The Debt Mountain and the Anderson Mandate

To ensure continuity during this turbulent phase, the supervisory board has extended the contracts of CEO Bill Anderson and pharma chief Stefan Oelrich through 2029. Anderson’s restructuring plan is now under the microscope, with investors demanding tangible progress on streamlining the group’s sprawling operations. The net debt, which stood at nearly €30 billion before the dividend payout, is a critical metric. Analysts will be watching closely when Bayer releases its first-quarter results on May 12, looking for signs of improved profitability in the Crop Science unit and stronger growth momentum from the new pharma products.

Despite the headwinds, management has reaffirmed its full-year guidance. Bayer expects 2026 revenue of up to €47 billion and an operating result of around €10 billion. But the legal overhang remains the dominant theme. Until the Supreme Court delivers its verdict, the €11.8 billion in provisions will continue to weigh on the balance sheet, and the search for a new CFO signals that the company is bracing for a long, hard road ahead.